The aim of this study was to evaluate the effect of benazepril addition to amlodipine antihypertensive treatment on ankle-foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP), two objective measures of ankle oedema. A total of 32 mild to moderate essential hypertensives (DBP490 and o110 mmHg), aged 30-70 years were studied. After a 4-week placebo period, they were randomized to amlodipine 5 mg o.d. or benazepril 10 mg o.d. or amlodipine 5 mg plus benazepril 10 mg o.d. for 4 weeks, according to a crossover design. At the end of the placebo period and of each active treatment period, blood pressure,AFV and PSTP were evaluated. AFV was measured using the principle of water displacement. PSTP was assessed using a system, the subcutaneous pretibial interstitial enviroment with a water manometer. Both amlodipine and benazepril monotherapy significantly reduced SBP (À18.2 7 4 and À17.8 7 4 mmHg, respectively, Po0.01 vs baseline) and DBP (À12.1 7 3 and À11.7 7 3 mmHg, respectively, Po0.01); the reduction was increased by the combination (À24.2 7 5 mmHg for SBP, Po0.001 and À16.8 7 4 mmHg for DBP, Po0.001). Amlodipine monotherapy significantly increased both AFV (+17.1%, Po0.001 vs baseline) and PSTP (+56.6%, Po0.001 vs baseline). As compared to amlodipine alone, the combination produced a less pronounced increase in AFV (+5.5%, Po0.05 vs baseline and Po0.01 vs amlodipine) and PSTP (+20.5%, Po0.05 vs baseline and Po0.01 vs amlodipine). Ankle oedema was clinically evident in 11 patients with amlodipine monotherapy and in three patients with the combination. These results suggest that ACE-inhibitors partially counteract the microcirculatory changes responsible for Ca-antagonists-induced oedema formation.
Introduction
Recent treatment guidelines for hypertension have suggested lower blood pressure (BP) goals to achieve the full benefits of antihypertensive therapy. 1, 2 Since most hypertensive patients are unlikely to reach the new BP targets with monotherapy, even at the highest dose of any antihypertensive drug, 3 the use of combinations of two agents has attracted increasing attention. Combining antihypertensive agents that lower BP by different mechanisms can allow better BP control providing additive antihypertensive effects while minimizing the likehood of dosedependent adverse effect. 4, 5 The combination of an angiotensin-converting enzyme inhibitor (ACE-I) with a calcium (Ca) antagonist is considered a rational approach, since it not only provides significantly better BP control than individual components used as monotherapy, but also results in a lower incidence of side effects. 6, 7 In particular, the ACE-I/Ca antagonist combination has been shown to reduce the incidence of the most common side effect of dihydropyridine Ca-antagonists, ankle oedema. [8] [9] [10] [11] Although the precise mechanisms causing the Ca-antagonist-induced oedema are still not completely understood, the most likely reason appears to be an increase in capillary hydrostatic pressure with consequent transcapillary fluid loss that results from a relatively more pronounced vasodilation in precapillary than postcapillary resistance vessels. [12] [13] [14] It has also been suggested that the Ca-antagonist-related oedema could be partly ascribed to interference by these drugs with the local vascular control (probably the myogenic component) that operates to protect dependent vascular regions from increased fluid filtration, 15, 16 whereas sodium retention and activation of the renin-angiotensin system seem to play a minor role. 14, 17 Most reports about the lower incidence of Caantagonist-induced ankle oedema with the addition of an ACE-I are generally based on a simple collection of reported side effects, that is, on subjective parameters rather than objective estimates of the magnitude of this effect. The present study was undertaken to evaluate objectively as to whether the addition of an ACE-I, benazepril, to the dihydropyridine Ca-antagonist amlodipine was able to attenuate ankle oedema formation in hypertensive patients treated for 4 weeks. To this purpose, we measured both ankle foot volume (AFV) and pretibial subcutaneous tissue pressure (PSTP). These two parameters, being differently related to tissue integrity and elasticity, provide complementary information on the potential for oedema formation of the drugs studied. AFV was determined with a device that uses Archimedes principle to measure water displacement induced by the immersion of the foot. PSTP was measured by a device, first described and validated by some German and Italian authors [18] [19] [20] [21] (for details, see the patients and methods section), that allows to connect the subcutaneous interstitial space of the leg with a water manometer.
Patients and methods
This was a randomized, double-blind, crossover study. Male and female outpatients, aged 30-70 years, with uncomplicated mild to moderate essential hypertension (DBP 490 and o110 mmHg after 4 weeks) were eligible. Exclusion criteria were evidence of significant cardiac, renal, endocrine or haematologic disease, pregnancy, known hypersensitivity to ACE-I or Ca-antagonists. Also excluded were patients with signs of venous insufficiency. None of the female patients were using oral contraceptives, which are known to affect subcutaneous tissue pressure and water retention.
The study protocol was approved by the local Ethical Committee and written informed consent was obtained from each patient before enrolment. After a 4-week placebo washout period, patients fulfilling the inclusion criteria were randomly assigned to treatment with amlodipine 5 mg o.d. or benazepril 10 mg or benazepril 5 mg plus amlodipine 10 mg for 4 weeks in three crossover periods, each separated by a 2-week placebo washout period.
The trial medications were provided in capsules of identical appearance (same size, taste and colour) and patients were required to take them between 8.00 and 10.00 am.
At the end of the placebo washout period and of each active treatment period, BP, heart rate (HR), AFV and PSTP were evaluated. BP was measured in the morning before daily drug intake (ie 24 h after dosing, at trough) using a standard mercury sphygmomanometer (Korotkoff I and V) after patients have been seated for 5 min. The average of three consecutive measurements, taken at an interval of X1 min, was recorded. HR was measured by radial pulse palpation at 30-s periods. AFV was measured using the principle of water displacement. For each measurement, a Perspex (Meditec, Pavia, Italy) water bath with a 15 l maximum capacity was filled with the same quantity of water; subsequent immersion of the foot induces water displacement that equals the immersed volume. This water was collected and measured. In order to reach a fixed and reproducible degree of immersion of the foot and ankle, a stable chair with adjustable height was used and patients maintained a rigidly standardized seated position with the thigh horizontal and the lower leg vertical. Three successive recordings were performed within 5 min and averaged; between recordings, the foot was withdrawn from the water bath and dried carefully and the water lost by removal was replaced before the next recording. In this test, foot volume recordings proved to be highly reproducible (coefficient of variation 0.30%). PSTP was assessed directly using the balancing open system, described by Lauderer 18 in 1884 and modified by Burch and Sodeman 19 in 1937, and the Malamani device. 20, 21 The method involves connecting the pretibial subcutaneous environment to a water manometer through a needle connected to a graduated capillary tube capped with a needle (Figure 1 ). Both the needle and the capillary tube are full of saline solution from the point of the needle to half-height of the tube, where the meniscus of the saline solution is visible. The needle is threaded into the subcutaneous pretibial tissue of the patient while he/she is lying in the supine position. Immediately after the needle is threaded into the subcutaneous tissue, the meniscus of the saline solution moves toward the manometer if the interstitial pressure is positive or toward the tissue if the interstitial pressure is negative. Using a micropump, the investigator attempts to achieve a pressure that does not produce any movement of the meniscus of the saline solution. Theoretically, the pressure read on the water manometer after saline solution balancing between manometer and interstitial tissue corresponds to the PSTP. Also in this test, three successive recordings were performed with a good reproducibility (coefficient of variation 0.25%).
Statistical analysis
Data are given as mean 7 s.d. The statistical analysis of the data was performed using SAS version 8.1 (SAS, Inc, Cary, NC, USA). For SBP and DBP, the treatment effect was evaluated by PROC GLM: variability sources considered were treatments and patients. The treatment effect on changes in AFV and PSTP was evaluated by nonparametric Wilcoxon's test. Spearman's rank test Effect of benazepril -amlodipine combination on ankle oedemawas also used for correlation analysis between these variables. In addition, 95% confidence intervals (CI) for mean and differences between treatments were calculated. Observed differences in data were considered significant if Po0.05.
Results
A total of 32 mild to moderate hypertensive patients, 14 males and 18 females, aged 30-70 years (mean age: 55. 2 7 9.1 years) were admitted to the study and none withdrew after randomization.
The main results of the study are reported in Table 1 . Both amlodipine and benazepril monotherapy significantly reduced BP values: the mean decrease in SBP/DBP values was 18.2 7 4/ 12.1 7 3 mmHg with amlodipine, Po0.01 vs baseline and 17.8 7 4/11.7 7 3 mmHg with benazepril, Po0.01 vs baseline. Combination therapy with benazepril+amlodipine produced a significantly greater reduction in BP values than either drug alone. The mean decrease in SBP/DBP was 24.2 7 5/ 16.8 7 4 mmHg, Po0.001 vs baseline, Po0.01 vs amlodipine and benazepril alone.
As expected, benazepril monotherapy did not modify AFV and PSTP as compared to baseline, whereas amlodipine monotherapy significantly increased both AFV (+14.2%, Po0.001 vs baseline) and PSTP (+56.6%, Po0.001 vs baseline). As compared to amlodipine alone, the benazepril+ amlodipine combination produced a significantly less pronounced increase in AFV (+5.5%, Po0.05 vs baseline and o0.01 vs amlodipine), the mean difference between the two treatments being statistically significant (139.6 ml, 95% CI 67.7, 188.3), and PSTP (+20.5%, Po0.05 vs baseline and o0.01 vs amlodipine), the mean difference between the two treatments being statistically significant (0.88 cm H 2 O, 95% CI 0.22, 1.18) (Figure 2 ). An inverse correlation was found between AFV and PSTP changes. With both amlodipine alone and benazepril+amlodipine combination, although to different degrees, the more pronounced increase in AFV corresponded to the less pronounced increase in PSTP and vice versa (correlation coefficients: À0.62, Po0.01 for amlodipine: À0.23, NS for amlodipine+benazepril) (Figure 3 ). Considering the correlations between age and treatment-induced changes in AFV and PSTP (Figure 4) , we observed that both amlodipine alone and benazepril+amlodi-pine combination, although to a different extent, produced increases in AFV that were greater with Effect of benazepril -amlodipine combination on ankle oedemaincreasing age. Conversely, the increase in PSTP caused by both treatments was reduced with increasing age. No significant correlation was found between the changes in AFV and PSTP, and the decrease in BP values induced by treatment with either amlodipine alone or with benazepril+amlodi-pine combination ( Figure 5 ). Ankle oedema was complained or was clinically evident in 11 patients with amlodipine alone and in three patients with the benazepril+amlodipine combination.
Discussion
In the present study, the addition of an ACE-I, benazepril, to a dihydropyridine Ca-antagonist, amlodipine, significantly attenuated lower extremity oedema, objectively evaluated through the measurement of AFV and PSTP. These findings are in agreement with previous observations based on spontaneously reported side effects in clinical trials [8] [9] [10] [11] and confirm and extend those of Weir et al, 22 who also used the water displacement technique to evaluate the effects of benazepril on the lower extremity oedema because of amlodipine.
The mechanism by which ACE-I attenuate the Ca-antagonist-induced oedema is not clear. The most likely explanation for this effect relates to the ability of ACE-I to dilate venous capacitance vessels, thereby normalizing intracapillary pressure and reducing fluid exudation from the intracapillary space into the interstitium. 14, 22 Owing to their ability to affect the vasodilatory mechanism Effect of benazepril -amlodipine combination on ankle oedema R Fogari et al of the oedema produced by Ca-antagonist, ACE-I seem to be more effective than diuretics (that merely diminish fluid retention) in attenuating this side effect. 14, 22 No relation was observed between the AFV and PSTP changes and the reduction in BP values induced by amlodipine monotherapy and by the benazepril+amlodipine combination; this allows to exclude that the attenuation of extremity oedema by the combination therapy was someway related to its antihypertensive effect. 14, 22 In both treatment groups, although at different degrees, younger patients showed the greatest increase in PSTP and the lowest increase in AFV, whereas the contrary was observed in the older patients. Such a different age-related response to the same stimulus for oedema formation confirms some previous observations by ourselves 23 and relates probably to the different structural characteristics of tissues at various ages. Younger patients have greater tissue integrity and more elastic tissue components so that the tendency toward fluid filtration may be counteracted by pronounced tension development in elastic tissue components with consequent increase in PSTP, that limits the AFV increase. In older patients, tissue relaxation and reduced elasticity of tissue components may be responsible for the lower tension in response to the same oedematigenous stimulus and favour fluid accumulation, with consequent greater increase in AFV than in PSTP.
No correlation was found between the AFV and PSTP changes and other patients characteristics, like sex, body weight and duration of hypertension. In this study, the addition of benazepril to amlodipine provided greater BP reduction than either drug alone, which confirms previous observations. Effect of benazepril -amlodipine combination on ankle oedema
